Trial Profile
A Randomized Phase III Study Comparing Docetaxel Followed by Cyclophosphamide, Epirubicin and 5-FU to Docetaxel With Capecitabine Followed by Cyclophosphamide, Epirubicin and Capecitabine as Adjuvant Treatment for Early Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Anastrozole; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil; Tamoxifen; Trastuzumab
- Indications Early breast cancer; HER2 positive breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms FinXX
- 06 Jun 2023 Results evaluating characteristics associated with each immune landscape, by deriving samples from this study, pepresented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 05 Feb 2022 Results(n=202) evaluating the BRCA1-like DNA copy number signature, indicative of homologous recombination deficiency, as a predictive biomarker for capecitabine benefit in the TNBC subgroup, published in the British Journal of Cancer
- 31 May 2020 Results of gene expression analysis and digital spatial profiling from two studies: FinXX trial and from the Mayo Clinic cohort of centrally reviewed TNBC (Leon-Ferre BCRT 2018) assessing specific subtypes and spatial distribution of tumor infiltrating lymphocytes presented at the 56th Annual Meeting of the American Society of Clinical Oncology